|Bid||0.00 x 800|
|Ask||49.85 x 900|
|Day's Range||48.72 - 49.85|
|52 Week Range||40.38 - 51.30|
|Beta (5Y Monthly)||0.38|
|PE Ratio (TTM)||24.90|
|Earnings Date||Feb 08, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||53.80|
Qiagen (QGEN) delivered earnings and revenue surprises of 12.77% and 3.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical diagnostics company Qiagen offset a sharp fall in demand for COVID-19 products at the end of the year with a strong performance in its core businesses, the company said, announcing its full-year and fourth quarter results on Tuesday. Fourth quarter revenues came in at $498 million, a 14% fall compared with the same period last year. Revenues from COVID products fell 64% to $66 million, but this was offset by strong growth in non-COVID products, where revenues rose 8% to $432 million.
VENLO, Netherlands, February 07, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the fourth quarter and full-year 2022.